All News

Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks.

Analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Although the ISMP created the guidelines for hospitals, they are applicable in other health care settings.

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Additionally, the safety profile in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified.

Asciminib offers a new option for patients harboring the T315I mutation.

This month, we spoke with Aaron Johnson, a fourth-year pharmacy student a the Nova Southeastern University College of Pharmacy.

When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis, and seizures significantly decline.

Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.

Zantac can treat and prevent heartburn, as well as treating stomach ulcers, gastroesophageal reflux disease, and conditions that cause too much stomach acid.

Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.

The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.

Medicaid expansion implementation was associated with a decrease in the number of uninsured patients from 6.7% pre-expansion to 3.6% post-expansion.

MIS-C is a rare complication of SARS-CoV-2 infection, which is characterized by symptoms such as fever, multiorgan involvement, and documented SARS-CoV-2 exposure.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discussed how investigative psychedelic-assisted therapy could help address both opioid addiction and chronic pain management.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses points of note in the evolution of lymphoma classification during her clinical and investigational research on the subject.

Heart-related complications in children with COVID-19 are uncommon, but case reports have noted cardiogenic shock, myocarditis, pericarditis, and arrhythmias.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses why a greater focus on colorectal cancer screening was important to highlight at the HOPA 2022 annual conference.

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

David Pope, PharmD, CDE, chief innovation officer at OmniSYS, discusses some of the technology trends that occurred in the pharmacy space during the pandemic.

In this month's episode, Staci Rush, clinical pharmacy technician at Hometown Pharmacy, discusses pharmacy intervention and how it can reduce hospital readmissions for patients.

Invega Hafyera is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

Theraful is a cold and flu medication that may help to relieve symptoms such as congestion, sore throat, aching, and fever.

An earlier clinical trial found a higher number of acute myocardial infarction events in those administered HepB-CpG vaccine versus those administered the HepB-alum vaccine.

Rita Roy, MD, CEO of the National Spine Health Foundation, discusses some alternative treatment plans for chronic back pain to help address the opioid epidemic.

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.